<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02923063</url>
  </required_header>
  <id_info>
    <org_study_id>52119-A</org_study_id>
    <nct_id>NCT02923063</nct_id>
  </id_info>
  <brief_title>Exercise Study Testing Enhanced Energetics of Muscle Mitochondria in CKD</brief_title>
  <acronym>ESTEEM-CKD</acronym>
  <official_title>A Randomized, Controlled Trial of Combined Aerobic and Resistance Exercise on Muscle Mitochondrial Function and Metabolism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Skeletal muscle dysfunction (sarcopenia) is an under-recognized target organ complication of
      CKD with substantial adverse clinical consequences of disability, hospitalization, and death.
      Sarcopenia in this proposal is defined by impaired metabolism and physical function
      associated with decreased skeletal muscle mass or function. Skeletal muscle tissue relies on
      mitochondria to efficiently utilize oxygen to generate ATP. Impaired mitochondrial energetics
      is a central mechanism of sarcopenia in CKD. The investigators propose a series of studies
      designed to shed light on the pathophysiology of sarcopenia in persons with CKD not treated
      with dialysis. Investigators will conduct a randomized-controlled intervention trial of
      combined resistance training and aerobic exercise vs. health education to assess changes in
      skeletal muscle mitochondrial function, metabolism and physical function. Investigators
      hypothesize that exercise improves mitochondrial function and physical function in persons
      with CKD. If successful, these experiments will identify novel pathophysiologic mechanisms
      for CKD-associated sarcopenia. The proposed study will provide useful insight into benefits
      associated with exercise among patients with CKD and investigate mechanisms associated with
      improved metabolism, muscle function and physical function in population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sarcopenia is a common complication of chronic kidney disease. Sarcopenia is defined by
      decreased muscle mass or function and is central to the frailty phenotype that is associated
      disability, hospitalization, and death. Sarcopenia is a common and devastating complication
      of chronic kidney disease (CKD). The investigators and others have demonstrated a high
      prevalence of physical frailty among CKD patients not treated with dialysis. Furthermore the
      investigators have demonstrated greater than 30% impairment in lower extremity physical
      performance measures in persons with CKD compared with predicted values. The aging
      demographic among CKD patients will result in a substantial U.S. public health burden
      attributable to sarcopenia. In the year 2000, direct healthcare costs attributable to
      sarcopenia in the U.S. were18.5 billion.

      Sarcopenia is associated with adverse health-related outcomes. Sarcopenia in older adults is
      consistently linked with decreased physical functioning, disability, falls, hospitalization,
      and mortality. Impaired lower extremity physical performance, as measured by objective
      testing, is associated with all-cause mortality in CKD patients not treated with dialysis and
      that these associations are stronger in magnitude than those for traditional risk factors.
      Skeletal muscle is major site of peripheral glucose utilization ameliorating oxidative stress
      and endothelial injury associated with acute post-prandial hyperglycemia. Through these
      mechanisms sarcopenia may contribute to metabolic disturbances of insulin resistance,
      oxidative stress, and endothelial dysfunction leading to cardiovascular disease.

      Mitochondrial dysfunction is central to skeletal muscle dysfunction. Skeletal muscle
      mitochondria are necessary for the efficient generation of energy (ATP) from oxygen and
      normal lipid metabolism. Under normal conditions, muscle efficiently utilizes the majority of
      supplied oxygen such that only 0.2% of mitochondrial oxygen is shuttled into reactive
      oxidative species (ROS). Under pathologic situations there is uncoupling of oxygen
      consumption and ATP generation resulting in increased oxygen consumption and decreased ATP
      production in a process leading to increased ROS and oxidative stress. Uncoupling of oxygen
      and ATP generation directly affects skeletal muscle function. Decreased efficiency of ATP
      generation has been linked to decreased muscle strength and more recently associated with
      decreased gait speed in older adults.

      Magnetic resonance spectroscopy and optical spectroscopy (MRS/OS) provide novel, non-invasive
      and real-time insight into human skeletal muscle mitochondrial function. MRS/OS is a novel
      technique that measures maximal mitochondrial ATP production in-vivo following acute bouts of
      ischemia induced by exercise using phosphorous MRS (31P MRS). The rate of recovery of
      phosphocreatinine after cessation of exercise is used to characterize the rate of aerobic
      mitochondrial ATP resynthesis above that of basal anaerobic glycolytic ATP production. By
      combining this technique with optical spectroscopy post-exercise measuring the transport of
      oxygen from hemoglobin to myoglobin within the muscle the investigators are able to
      accurately determine the ratio of coupling efficiency between of ATP generation per unit of
      oxygen consumption. Skeletal muscle mitochondrial dysfunction measured by ATP generating
      capacity and coupling efficiency has been associated with processes of aging and insulin
      resistance. Furthermore studies in healthy subjects have shown that muscle performance and
      fatigue are linked to the ability to resynthesize ATP rather than lactate concentration.

      Preliminary MRS/OS findings suggest profoundly altered mitochondrial function in CKD
      patients. Previous experimental studies suggest that uremia in dialysis patients affects
      skeletal muscle structure and mitochondrial function. Oxidative damage is highly prevalent in
      CKD, evidenced by increased biomarkers of oxidative stress and changes in glutathione, an
      important antioxidant. Prior small studies in non-diabetic CKD patients suggest impairment of
      ex-vivo mitochondrial function by reductions in mitochondrial enzyme activity. Based on these
      findings investigators used novel, non-invasive, functional MRS/OS assay to characterize
      in-vivo mitochondrial function. Preliminary findings in non-diabetic CKD patients indicate
      markedly reduced ATP to oxygen ratio compared to controls. This finding suggests altered
      mitochondrial energetics as a candidate central mechanism linking metabolic derangements and
      impaired physical function in CKD, and motivate the hypothesis that mitochondrial dysfunction
      is associated with oxidative stress, insulin resistance and impaired physical functioning in
      CKD.

      Exercise may ameliorate mitochondrial dysfunction, insulin resistance and physical
      functioning in CKD. Studies of exercise in non-CKD patients with diabetes and insulin
      resistance have demonstrated exercise-induced improvements in mitochondrial biogenesis linked
      to improved insulin sensitivity as well as decreased mitochondrial oxidative stress. Animal
      studies suggest that exercise stimulates autophagy resulting in removal of defective and
      inefficient mitochondrial leading to a healthy mitochondrial network and improved insulin
      sensitivity.The primary goal of this study is to investigate the impact of combined
      resistance and aerobic exercise on skeletal muscle dysfunction. Given the investigator's
      preliminary data demonstrating strong association of sarcopenia and mortality in CKD,
      effective interventions that can impact physical function are urgently needed to improve
      patient health outcomes.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mitochondrial phosphorylation capacity (ATPmax) by in-vivo 31P MRS/OS</measure>
    <time_frame>12 weeks</time_frame>
    <description>Hand and leg muscles</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mitochondrial coupling efficiency (ATP/O2 or P/O) by in-vivo 31P MRS/OS</measure>
    <time_frame>12 weeks</time_frame>
    <description>Hand and leg muscles</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in physical performance</measure>
    <time_frame>12 weeks</time_frame>
    <description>6 minute walking distance (meters)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Systemic oxidative stress (markers of arachidonic acid peroxidation)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Plasma isofurans (pg/min)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Muscle Mitochondrial nicotinamide-adenine dinucleotide phosphate from in-vivo MRS</measure>
    <time_frame>12 weeks</time_frame>
    <description>mM (millimole)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in aerobic capacity (VO2max) (ml/kg/min)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in muscle fatigue</measure>
    <time_frame>12 weeks</time_frame>
    <description>Force-time integral (Newtons/second)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Muscle mitochondrial reactive oxygen species production from permeabilized muscle fibers.</measure>
    <time_frame>12 weeks</time_frame>
    <description>hydrogen peroxide (H2O2) production (pmol/min/mg protein)</description>
  </other_outcome>
  <other_outcome>
    <measure>Monocyte bioenergetics</measure>
    <time_frame>12 weeks</time_frame>
    <description>Reserve Capacity (pmo/min/mcg protein)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Moderate-severe Chronic Kidney Disease Not Treated With Dialysis</condition>
  <condition>Non-insulin Dependent Diabetic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Combined Aerobic and Resistance Exercise</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Exercise will be supervised by American College of Sports Medicine certified exercise trainers 3 days per week for 12 weeks. Subjects in the exercise intervention arms will undergo supervised low-impact aerobic intervention sessions of 30-minute duration at 60-80% of the maximal heart rate and 30 minutes of resistance exercise training target 60% of single repetition maximal lift (1RM) three times per week. Investigators will use the Balke protocol for treadmill aerobic exercise. Investigators will encourage adherence to the treadmill exercise, however, if the participant declines to use of the treadmill for the day, they will be given other aerobic exercise options (elliptical trainer, cycle, etc.) targeting the same duration and goal heart rate.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>At the beginning of the intervention phase, the control group will receive a one-time counseling session on appropriate dietary and physical activity recommendations. They will receive a &quot;Go4Life Workout to go&quot; sample exercise routing created by the national institutes on aging (NIA).</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Combined Aerobic and Resistance Exercise</intervention_name>
    <arm_group_label>Combined Aerobic and Resistance Exercise</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Moderate-severe CKD determined by estimated glomerular filtration rate (eGFR)
             &lt;60ml/min per 1.73m2

          -  No history chronic treatment with dialysis.

          -  Age 18 years old to 75 years

        Exclusion Criteria:

          -  Current or previous transplantation

          -  Current pregnancy

          -  Wheelchair dependence

          -  Oxygen dependent Chronic obstructive pulmonary disease (COPD)

          -  Shortness of breath after walking &lt;100 steps on flat surface

          -  Weight &gt;300 pounds

          -  Arm &lt; 47 cm long

          -  HIV infection

          -  Liver cirrhosis

          -  Active malignant cancer other than non-melanomatous skin cancer

          -  Drugs that alter mitochondrial function:

               -  muscle relaxants (methocarbamol, baclofen, tizanidine, carisoprodol,
                  cyclobenzaprine)

               -  oral steroids (Equivalent of 10mg or more of prednisone daily)

               -  anti-viral medications (tenofovir, zalcitabine, didanosine, stavudine,
                  lamivudine, zidovudine, abacavir, adefovir, interferon, ribavirin, efavirenz,
                  dasabuvir, ombitasvir)

               -  oral calcineurin inhibitors (Tacrolimus, Cyclosporine)

               -  Antiepileptic drugs (Phenytoin, phenobarbital, carbamazepine, valproic acid,
                  oxcarbazepine, ethosuximide, zonisamide, topiramate, and vigabatrin)

               -  Antipsychotics (haloperidol, thioridazine, risperidone, quetiapine, clozapine,
                  olanzapine and aripiprazole)

          -  Drugs- anticoagulants or antiplatelets

               -  Anticoagulants, any 1 (coumadin, rivaroxaban, apixaban, dabigatran, edoxaban)

               -  Antiplatelets, any 2 (aspirin, cilostazol, clopidogrel, dipyridamole, prasugrel,
                  ticagrelor, ticlopidine, vorapaxar)

          -  Implants that prohibit MRI measurements or trauma involving metal fragments

          -  Pacemaker

          -  History of deep venous thrombosis (DVT) or Pulmonary Embolism (PE)

          -  Vascular stent: bare metal or any recently placed (within 6 months)

          -  Current substance abuse

          -  Pain in arm or leg that would limit laying still for 3-4 hours or undergoing ischemia

          -  Polycythemia or thrombocytosis

          -  Urine protein/creatinine ratio â‰¥ 3.5 grams

          -  Institutionalization

          -  Current participation in an interventional trial

          -  Inability to provide informed consent without a proxy respondent

          -  Non-English speaking

          -  Any condition which in the judgement of the clinical investigator places the
             participant at risk from participation in the study.

        Additional Criteria:

          -  On chronic dialysis

          -  Expectation to start dialysis within 6 months.

          -  Insulin dependent diabetes

          -  Baseline systolic blood pressure &gt;170 or diastolic blood pressure &gt;100
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Baback Roshanravan, MD MS MSPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kidney Research Institute, University of Washington</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bryan Kestenbaum, MD MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kidney Research Institute, University of Washington</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jonathan Himmelfarb, MD</last_name>
    <role>Study Director</role>
    <affiliation>Kidney Research Institute, University of Washington</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ian H de Boer, MD MS</last_name>
    <role>Study Director</role>
    <affiliation>Kidney Research Institute, University of Washington</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kevin E Conley, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University of Washington Translational Center for Metabolic Imaging</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Baback Roshanravan, MD MS MSPH</last_name>
    <phone>2067443948</phone>
    <email>broshanr@uw.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kidney Research Institute, University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bob Roshanravan, MD MS MSPH</last_name>
      <phone>206-744-3948</phone>
      <email>broshanr@uw.edu</email>
    </contact>
    <investigator>
      <last_name>Jonathan Himmelfarb, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bryan Kestenbaum, MD MS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bob Roshanravan, MD MS MSPH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 29, 2016</study_first_submitted>
  <study_first_submitted_qc>October 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 4, 2016</study_first_posted>
  <last_update_submitted>October 4, 2016</last_update_submitted>
  <last_update_submitted_qc>October 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Bob Roshanravan</investigator_full_name>
    <investigator_title>Acting Instructor</investigator_title>
  </responsible_party>
  <keyword>Chronic Kidney Disease</keyword>
  <keyword>Mitochondrial Metabolism</keyword>
  <keyword>Physical Performance</keyword>
  <keyword>Exercise Intolerance</keyword>
  <keyword>Muscle Fatigue</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

